Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction (Q34676533)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

G-protein beta3 Subunit Gene 825C/T Polymorphism Is Not Associated with Olanzapine-Induced Weight Gain in Korean Schizophrenic Patients.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Genomewide association study of movement-related adverse antipsychotic effects

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Genomewide association studies: history, rationale, and prospects for psychiatric disorders

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Excess of transmission of the G allele of the -1438A/G polymorphism of the 5-HT2A receptor gene in patients with schizophrenia responsive to antipsychotics

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Schizophrenia: a concise overview of incidence, prevalence, and mortality

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Tardive dyskinesia and new antipsychotics

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Association of dopamine receptor polymorphisms with schizophrenia and antipsychotic response in a South Indian population

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Serotonin transporter gene variants and behavior: a comprehensive review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

The AmpliChip CYP450 genotyping test: Integrating a new clinical tool

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Negative symptoms of schizophrenia could explain discrepant data on the association between the 5-HT2A receptor gene and response to antipsychotics

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Half a century of antipsychotics and still a central role for dopamine D2 receptors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Clinical applications of pharmacogenetics in psychiatry

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Dopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophrenia.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Failure to respond to treatment with typical antipsychotics is not associated with CYP2D6 ultrarapid hydroxylation.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Clozapine response and the 5HT2C Cys23Ser polymorphism.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

5-HT2 receptor gene locus: association with schizophrenia or treatment response not detected.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Cytochrome P4502D6 genotype does not determine response to clozapine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Cytochrome P-450 in the brain. Potential evolutionary and therapeutic relevance of localization of drug-metabolizing enzymes

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

7 July 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Allele C-specific methylation of the 5-HT2A receptor gene: evidence for correlation with its expression and expression of DNA methylase DNMT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Effects of the DRD3 Ser9Gly polymorphism on aripiprazole efficacy in schizophrenic patients as modified by clinical factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Risperidone response and 5-HT6 receptor gene variance: genetic association analysis with adjustment for nongenetic confounders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Pharmacogenetic prediction of clozapine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Response of risperidone treatment may be associated with polymorphisms of HTT gene in Chinese schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Catechol-O-methyltransferase and monoamine oxidase A genotypes and drug response to conventional neuroleptics in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Meta-analysis of the cognitive effects of the catechol-O-methyltransferase gene Val158/108Met polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Risperidone plasma levels, clinical response and side-effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

II. Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinine oxidoreductase 1 (NQO1) and Superoxide dismutase 2 (SOD2, MnSOD) genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Association of antipsychotic induced weight gain and body mass index with GNB3 gene: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Association between TaqI A dopamine D2 receptor polymorphism and therapeutic response to bromperidol: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

The dopamine D3 receptor (DRD3) Ser9Gly polymorphism and schizophrenia: a haplotype relative risk study and association with clozapine response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Dopamine D3 receptor Ser9Gly polymorphism and risperidone response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Investigation of possible association between Ser9Gly polymorphism of the D3 dopaminergic receptor gene and response to typical antipsychotics in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizoprenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Allelic Variation in the D4 Dopamine Receptor (DRD4) Gene Does Not Predict Response to Clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Genetic variation of the 5-HT2A receptor and response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Association between a polymorphism in the promoter region of the dopamine D2 receptor gene and schizophrenia in Japanese subjects: replication and evaluation for antipsychotic-related features

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: a preliminary finding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene ⋆

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Age and the relationship of dopamine D3, serotonin 2C and serotonin 2A receptor genes to abnormal involuntary movements in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Negative association between catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

-759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

-759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Association study of adrenergic beta3 receptor (Trp64Arg) and G-protein beta3 subunit gene (C825T) polymorphisms and weight change during clozapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: a meta-analysis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

CYP2D6*3, *4, *5 AND *6 POLYMORPHISMS AND ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL SIDE-EFFECTS IN PATIENTS RECEIVING ANTIPSYCHOTIC THERAPY

26 October 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Pharmacogenetics of clozapine response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Dopamine D4 receptor subtypes and response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene (DRD4) in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Genetic variation of 5-HT2A receptor and response to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Dopamine D3 receptor variant and tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2011.532787

5HT 2a receptor T102C polymorphism and schizophrenia

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3057913

The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia

26 October 2018

1 reference

12 December 2020

Allelic association between a Ser-9-Gly polymorphism in the dopamine D3 receptor gene and schizophrenia

1 reference

12 December 2020

Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans

1 reference

12 December 2020

Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine

1 reference

12 December 2020

Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients

1 reference

12 December 2020

DRD3 and DAT1 genes in schizophrenia: an association study

1 reference

12 December 2020

Serotonin-6 receptor variant (C267T) and clinical response to clozapine

1 reference

12 December 2020

Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism

1 reference

12 December 2020

Evidence for an Association between the Dopamine D3 Receptor Gene DRD3 and Schizophrenia

1 reference

12 December 2020

Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients

1 reference

12 December 2020

Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response

1 reference

12 December 2020

Catechol-O-methyltransferase val108/158met genotype and response to antipsychotic medication in schizophrenia

1 reference

12 December 2020

Association between clozapine response and allelic variation in the 5-HT2C receptor gene

1 reference

12 December 2020

Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics

1 reference

12 December 2020

Association between clozapine response and allelic variation in 5-HT2A receptor gene

1 reference

12 December 2020

Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms

1 reference

12 December 2020

Association study of a functional serotonin transporter gene polymorphism with schizophrenia, psychopathology and clozapine response

1 reference

12 December 2020

Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects

1 reference

12 December 2020

The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients

1 reference

12 December 2020

Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia

1 reference

12 December 2020

Assessment of association of D3 dopamine receptor MscI polymorphism with schizophrenia: analysis of symptom ratings, family history, age at onset, and movement disorders

1 reference

12 December 2020

CYP2D6 Polymorphism and Tardive Dyskinesia in Schizophrenic Patients

1 reference

12 December 2020

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients

1 reference

12 December 2020

Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia

1 reference

12 December 2020

No evidence for association of serotonin-2A receptor variant (102T/C) with schizophrenia or clozapine response in a Chinese population

1 reference

12 December 2020

Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia

1 reference

12 December 2020

Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study

1 reference

12 December 2020

The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients

1 reference

12 December 2020

Effects of the dopamine D3 receptor (DRD3) gene polymorphisms on risperidone response: a pharmacogenetic study

1 reference

12 December 2020

Dopamine receptors, neuroleptics, and schizophrenia

1 reference

12 December 2020